SCHEMBL25327386

SCHEMBL25327386

N#CC1CC2(C1)CN(C(=O)N1CC3(CN(Cc4ccc(F)cc4F)C3)C1)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ GPR183 P32249 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.38
▸ DPP4 P27487 1/20 0.37
▸ FAP Q12884 1/20 0.37
▸ DPP8 Q6V1X1 1/20 0.37
▸ DPP9 Q86TI2 1/20 0.37
▸ DPP7 Q9UHL4 1/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ GLA P06280 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ CYP2D6 P10635 1/20 0.35
▸ USP30 Q70CQ3 2/20 0.35
▸ GPR6 P46095 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25326091 0.79 ALDH1A1 (0.39) ALDH1A1KDM4ESMN1; SMN2TDP1GPR183
SCHEMBL25325519 0.77 MAPT (0.39) ALDH1A1KDM4ESMN1; SMN2TDP1GPR183
SCHEMBL27150520 0.75 MGLL (0.53) ALDH1A1KDM4ESMN1; SMN2TDP1HDAC6
SCHEMBL25323897 0.75 ALDH1A1 (0.35) ALDH1A1KDM4ESMN1; SMN2TDP1GPR183
SCHEMBL30700120 0.70 ALDH1A1 (0.38) ALDH1A1KDM4ESMN1; SMN2TDP1GPR6
SCHEMBL27139040 0.69 MGLL (0.36) ALDH1A1TDP1DPP4GPR6MEN1
SCHEMBL25324305 0.68 KDM4E (0.55) ALDH1A1KDM4ESMN1; SMN2TDP1HDAC6
SCHEMBL25328161 0.68 GPR183 (0.47) GPR183MGLL
SCHEMBL23850086 0.67 MEN1 (0.52) ALDH1A1KDM4ESMN1; SMN2TDP1GPR183
SCHEMBL23150537 0.67 HTR2A (0.40) ALDH1A1KDM4ESMN1; SMN2TDP1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 ALDH1A1 411/4885KDM4E 1137/4885SMN1; SMN2 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback